Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
May 09, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
May 08, 2024 16:05 ET
|
Tarsus Pharmaceuticals, Inc
Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and...
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024 17:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
April 23, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate at Upcoming Investor Conferences
March 05, 2024 16:30 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
March 05, 2024 08:30 ET
|
Tarsus Pharmaceuticals, Inc
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25...
Tarsus Announces Pricing of $100.0 Million Public Offering
March 01, 2024 00:07 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
Tarsus Announces Proposed $100.0 Million Public Offering
February 29, 2024 16:37 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new...
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
February 27, 2024 06:00 ET
|
Tarsus Pharmaceuticals, Inc
Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four...
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
February 22, 2024 08:00 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...